Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071560 | 0.86 | SSTR4 (0.41) | SSTR4F2F10F7HDAC1 | |
| SCHEMBL4081699 | 0.85 | SSTR4 (0.45) | SSTR4F2F10F7HDAC1 | |
| SCHEMBL28466070 | 0.79 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2LPAR1 | |
| SCHEMBL14369645 | 0.75 | SSTR4 (0.36) | SSTR4LPAR1LPAR5AAK1 | |
| SCHEMBL14529895 | 0.75 | SSTR4 (0.38) | SSTR4HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL4257993 | 0.74 | GRM2 (0.36) | SSTR4F2F10F7HDAC1 | |
| SCHEMBL4488726 | 0.74 | F2 (0.41) | SSTR4F2F10F7HDAC1 | |
| SCHEMBL15127576 | 0.74 | GRM2 (0.41) | SSTR4HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL10305081 | 0.74 | GRM2 (0.41) | SSTR4HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4075808 | 0.74 | SSTR4 (0.42) | SSTR4LPAR1LPAR5AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730140-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288543-B2 | For therapy or prophylaxis of obesity and related diseases including eating disorders (bulimia, anorexia nervosa, etc.), diabetes, diabetic complications, diabetic retinopathy, sexual/reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage | ELI LILLY AND COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070179129-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2007-08-02 | — | — | US | disclosed |
| EP-1730140-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090337-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179129-A1 | Opioid receptor antagonists | OPRK1, OPRM1, OPRL1 | SSTR4 553/4885F2 2502/4885F10 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.